About Jubilant Pharmova Limited
Data last updated: 15 July 2026
Jubilant Pharmova Limited is a public limited company based in U P, Uttar Pradesh, India. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 21 June 1978, the company has been in operation for over 48 years.
Registered with ROC Uttar Pradesh under CIN L24116UP1978PLC004624. Listed on BSE: 530019 and NSE: JUBLPHARMA.
Capital: an authorised share capital of ₹143.02 Cr and a paid-up capital of ₹15.93 Cr. Formerly known as Vam Organic Chemicals Limited and Jubilant Organosys Limited. It is led by directors including Priyavrat Bhartia and Arun Seth.
Last AGM: 29 August 2025. Financial statements filed for year ended 31 March 2025. Office: Bhartiagram Gajraulajyotiba Phoolay Nagar, U P, Uttar Pradesh, India – 244223.
As per NSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹8,279.6 Cr, a growth of 14.45% compared to the previous year. The net worth stands at ₹7,095.6 Cr (up 13.74% YoY). Total assets are valued at ₹15,523 Cr (up 21.69% YoY).
The company has a workforce of approximately 1,055 employees as per the latest available data. Its group structure includes 7 subsidiaries.
The company is associated with 3 brands - Jubilant Biosys, Jubilant Life Sciences, Jubilant Pharmova. As per MCA filings, the company has open charges of ₹260 Cr and satisfied charges of ₹9,285.57 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website jubilantpharmova.com.
-
EmailLocked
-
TelephoneLocked
-
Website
-
Social Media
-
Registered AddressBhartiagram Gajraulajyotiba Phoolay Nagar, U P, Uttar Pradesh, India – 244223
-
IndustryPharma, API Manufacturers
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Jubilant Pharmova Limited
Jubilant Pharmova Limited has undergone 3 name changes throughout its history. The company was previously known as Vam Organic Chemicals Limited, Jubilant Organosys Limited, and Jubilant Life Sciences Limited. The current legal name is Jubilant Pharmova Limited, reflecting the company's evolution and rebranding over time.
| Company Name | Status |
|---|---|
| Jubilant Pharmova Limited | Current |
| Vam Organic Chemicals Limited | Previous |
| Jubilant Organosys Limited | Previous |
| Jubilant Life Sciences Limited | Previous |
CIN History of Jubilant Pharmova Limited
Jubilant Pharmova Limited has one previous CIN (Corporate Identification Number): U24116UP1978PLC004624. The current CIN is L24116UP1978PLC004624, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24116UP1978PLC004624 | Current |
| U24116UP1978PLC004624 | Previous |
Associated Brands with Jubilant Pharmova Limited
Jubilant Pharmova Limited operates multiple associated brands including Jubilant Biosys, Jubilant Life Sciences, and Jubilant Pharmova. These brands represent Jubilant Pharmova Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Offers integrated drug discovery, research, and manufacturing for pharmaceuticals. | jubilantbiosys.com | |
| Company offering a suite of R&D and manufacturing services for small molecules and generics | jubl.com | |
| CDMO focused on manufacturing of solid, semi solid, liquid, and injectible drug formulations | jubilantpharmova.com |
Competitors & Alternatives of Jubilant Pharmova Limited
Brands and companies operating in the same space as Jubilant Pharmova Limited include Evotec, Akums, Crown Bioscience and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Evotec
|
Drug discovery and development services are provided to biopharma sector. | Hamburg, Germany, Germany | 1993 |
Akums
|
CDMO focusing on spectrum of dosage forms and therapeutic segments | Delhi, India, India | 2004 |
Crown Bioscience
|
Cancer and CVMD drugs are developed using PDX models. | Santa Clara, United States, United States | 2006 |
NIH
|
Drug discovery services are provided to the biopharma sector. | United States | 1887 |
Domainex
|
Drug discovery CRO company for epigenetic research and inflammatory diseases | Cambridge, United Kingdom, United Kingdom | 2001 |
Nectar Lifesciences
|
Cephalosporin APIs and generic formulations are manufactured. | Chandigarh, India, India | 1995 |
Windlas
|
Biopharma regulatory affairs, quality control, and strategy services are provided. | Gurugram, India, India | 2001 |
Unither
|
Contract development and manufacturing organization for proprietary and generic drugs | Paris, France, France | 1993 |
Alloy Therapeutics
|
Drug discovery services are provided for therapeutic development. | Lexington, United States, United States | 2017 |
Recipharm
|
Pharmaceutical development and manufacturing services are offered contractually. | Jordbro, Sweden, Sweden | 1995 |
Business Activity of Jubilant Pharmova Limited
Jubilant Pharmova Limited is engaged in principal business activities including professional, scientific and technical and manufacturing, with detailed activities including management consultancy activities, chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products. The company has 2 registered principal business activity segments, demonstrating its operational diversity and market reach.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M3 | Management consultancy activities | Locked |
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details for Jubilant Pharmova Limited
Turnover contribution percentages and historical activity changes require an active report plan.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Auditor Details of Jubilant Pharmova Limited
Jubilant Pharmova Limited is audited by Walker Chandiok & Co LLP (ICAI peer reviewed, certificate valid till 2028-05-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| Walker Chandiok & Co LLP (ICAI peer reviewed, certificate valid till 2028-05-31) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Jubilant Pharmova Limited
Jubilant Pharmova Limited is currently managed by 10 directors, with 32 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Priyavrat Bhartia | Managing Director | 23 May 2017 | 9 Years 2 Months | Current |
|
Arun Seth
Also directs:
Jubilant Ingrevia Limited, Trinetra Business Advisors India Llp, Dixon Technologies (India) Limited and 5 more
|
Director | 22 Oct 2018 | 7 Years 10 Months | Current |
|
Hari Shanker Bhartia
Also directs:
Jubilant Ingrevia Limited, Jubilant Foodworks Limited, Jubilant Enpro Private Limited and 5 more
|
Director | 01 Nov 1983 | 42 Years 9 Months | Current |
| Arjun Shanker Bhartia | Managing Director | 23 May 2017 | 9 Years 2 Months | Current |
| Shyam Sunder Bhartia | Director | 21 Jun 1978 | 48 Years 2 Months | Current |
|
Vivek Mehra
Also directs:
Chambal Fertilisers And Chemicals Limited, Ht Media Limited, Vivek Mehra Llp and 5 more
|
Director | 23 May 2017 | 9 Years 2 Months | Current |
Financials of Jubilant Pharmova Limited FY 2026 filings available
Jubilant Pharmova Limited reported revenue of ₹8,279.6 Cr (up 14.45% YoY) for FY 2026.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue from Operations | ₹8,279.6 Cr | ₹7,234.5 Cr | ₹670.29 Cr | ₹6,281.73 Cr | ₹6,059.17 Cr | ₹9,154.41 Cr |
| Other Income | ₹66 Cr | ₹56.8 Cr | ₹6.87 Cr | ₹38.33 Cr | ₹82.28 Cr | ₹47.43 Cr |
| Total Income | ₹8,345.6 Cr | ₹7,291.3 Cr | ₹677.16 Cr | ₹6,320.06 Cr | ₹6,141.45 Cr | ₹9,201.84 Cr |
| Cost of Materials Consumed | ₹2,320.3 Cr | ₹1,985.3 Cr | ₹182.13 Cr | ₹1,666.41 Cr | ₹1,348.7 Cr | ₹3,119.42 Cr |
| Purchases of Stock-in-Trade | ₹313.1 Cr | ₹297.1 Cr | ₹24.12 Cr | ₹252.22 Cr | ₹201.62 Cr | ₹276.58 Cr |
| Changes in Inventories | ₹10.9 Cr | ₹34.6 Cr | ₹7.82 Cr | -₹40.7 Cr | -₹62.32 Cr | -₹255.43 Cr |
| Employee Benefit Expense | ₹2,700.6 Cr | ₹2,267.9 Cr | ₹221.6 Cr | ₹2,166.02 Cr | ₹2,043.39 Cr | ₹2,127.68 Cr |
| Finance Costs | ₹211.8 Cr | ₹240.3 Cr | ₹27.23 Cr | ₹188.2 Cr | ₹145.49 Cr | ₹287.41 Cr |
| Depreciation & Amortisation | ₹440.4 Cr | ₹368.6 Cr | ₹38.19 Cr | ₹554.03 Cr | ₹381.7 Cr | ₹461.93 Cr |
| Other Expenses | ₹1,674.9 Cr | ₹1,475.9 Cr | ₹144.54 Cr | ₹1,461.53 Cr | ₹1,442.44 Cr | ₹1,939.08 Cr |
| Total Expenses | ₹7,672 Cr | ₹6,669.7 Cr | ₹645.63 Cr | ₹6,247.71 Cr | ₹5,501.02 Cr | ₹7,956.67 Cr |
| Profit Before Exceptional Items & Tax | ₹673.6 Cr | ₹621.6 Cr | ₹31.53 Cr | ₹72.35 Cr | ₹640.43 Cr | ₹1,245.17 Cr |
| Exceptional Items | -₹59.2 Cr | ₹359.5 Cr | -₹16.89 Cr | -₹56.82 Cr | ₹0 | -₹34.64 Cr |
| Profit Before Tax | ₹614.4 Cr | ₹981.1 Cr | ₹14.64 Cr | ₹15.53 Cr | ₹640.43 Cr | ₹1,210.53 Cr |
| Total Tax Expense | ₹216.6 Cr | ₹144.3 Cr | ₹9.78 Cr | ₹92.66 Cr | ₹217.43 Cr | ₹312.29 Cr |
| Net Profit | ₹397.5 Cr | ₹836.3 Cr | ₹7.27 Cr | -₹64.88 Cr | ₹413.02 Cr | ₹898.24 Cr |
| attributable to Owners | ₹398.5 Cr | ₹839.4 Cr | ₹7.71 Cr | -₹60.98 Cr | ₹413.94 Cr | ₹898.24 Cr |
| attributable to NCI | -₹1 Cr | -₹3.1 Cr | -₹44 Lakh | -₹3.9 Cr | -₹92 Lakh | - |
| Other Comprehensive Income | ₹545.8 Cr | ₹85 Cr | ₹5.44 Cr | ₹220.43 Cr | ₹243.96 Cr | ₹33.11 Cr |
| Total Comprehensive Income | ₹943.3 Cr | ₹921.3 Cr | ₹12.71 Cr | ₹155.55 Cr | ₹656.98 Cr | ₹931.35 Cr |
| EBITDA (computed) | ₹1,325.8 Cr | ₹1,230.5 Cr | ₹96.95 Cr | ₹814.58 Cr | ₹1,167.62 Cr | ₹1,994.51 Cr |
| Basic EPS | ₹25.15 | ₹52.99 | ₹4.87 | ₹-3.83 | ₹26.00 | ₹56.39 |
| Diluted EPS | ₹25.08 | ₹52.85 | ₹4.86 | ₹-3.83 | ₹26.00 | ₹56.39 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹15,523 Cr | ₹12,756 Cr | ₹1,154.85 Cr | ₹11,157 Cr |
| Non-current Assets | ₹11,413 Cr | ₹9,179.2 Cr | ₹767.24 Cr | ₹7,394.25 Cr |
| Current Assets | ₹4,109.3 Cr | ₹3,509.7 Cr | ₹363.22 Cr | ₹3,762.4 Cr |
| Property, Plant & Equipment | ₹3,509.6 Cr | ₹2,132.3 Cr | ₹215.78 Cr | ₹2,297.53 Cr |
| Inventories | ₹1,231.5 Cr | ₹1,129.2 Cr | ₹128.96 Cr | ₹1,380.53 Cr |
| Trade Receivables | ₹1,069.6 Cr | ₹891.5 Cr | ₹91.59 Cr | ₹961.24 Cr |
| Cash & Equivalents | ₹1,267.1 Cr | ₹1,088.3 Cr | ₹95.64 Cr | ₹1,013.92 Cr |
| Equity (Net Worth) | ₹7,095.6 Cr | ₹6,238.6 Cr | ₹542.11 Cr | ₹5,391.79 Cr |
| Equity Share Capital | ₹15.8 Cr | ₹15.8 Cr | ₹1.58 Cr | ₹15.91 Cr |
| Borrowings (Non-current) | ₹2,971.7 Cr | ₹2,150.3 Cr | ₹316.71 Cr | ₹3,110.36 Cr |
| Borrowings (Current) | ₹247.8 Cr | ₹286.6 Cr | ₹24.7 Cr | ₹299.72 Cr |
| Total Debt (computed) | ₹3,219.5 Cr | ₹2,436.9 Cr | ₹341.41 Cr | ₹3,410.08 Cr |
| Current Liabilities | ₹2,538.9 Cr | ₹2,164.6 Cr | ₹188.9 Cr | ₹1,772.4 Cr |
| Total Liabilities | ₹8,427.1 Cr | ₹6,517.8 Cr | ₹612.74 Cr | ₹5,764.86 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹1,226.8 Cr | ₹1,072.1 Cr | ₹97.13 Cr | ₹660.67 Cr | ₹837.54 Cr |
| Investing Cash Flow | -₹1,260 Cr | ₹487.7 Cr | -₹60.79 Cr | -₹544.41 Cr | -₹380.37 Cr |
| Financing Cash Flow | ₹94.9 Cr | -₹1,452.7 Cr | -₹43.25 Cr | -₹156.69 Cr | -₹32.6 Cr |
| Capital Expenditure | ₹1,449.1 Cr | ₹1,115.6 Cr | ₹89.77 Cr | ₹814.45 Cr | ₹599.99 Cr |
| Free Cash Flow (computed) | -₹222.3 Cr | -₹43.5 Cr | ₹7.36 Cr | -₹153.78 Cr | ₹237.55 Cr |
| Dividends Paid | ₹79.5 Cr | ₹79.6 Cr | ₹7.98 Cr | ₹80.06 Cr | ₹80.05 Cr |
| Net Change in Cash | ₹178.8 Cr | ₹131.9 Cr | -₹5.75 Cr | ₹30.1 Cr | ₹481.86 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹2,290 Cr | ₹2,122.5 Cr | ₹1,966.4 Cr | ₹1,900.7 Cr | ₹1,928.8 Cr | ₹1,821.7 Cr | ₹1,752.3 Cr | ₹1,731.7 Cr | ₹175.86 Cr | ₹1,677.1 Cr | ₹1,680.3 Cr | ₹1,586.9 Cr |
| Other Income | ₹23.7 Cr | ₹20.5 Cr | ₹9.8 Cr | ₹12 Cr | ₹11.9 Cr | ₹9.2 Cr | ₹21.7 Cr | ₹14 Cr | ₹1.44 Cr | ₹35.8 Cr | ₹9.9 Cr | ₹8.6 Cr |
| Total Income | ₹2,313.7 Cr | ₹2,143 Cr | ₹1,976.2 Cr | ₹1,912.7 Cr | ₹1,940.7 Cr | ₹1,830.9 Cr | ₹1,774 Cr | ₹1,745.7 Cr | ₹177.3 Cr | ₹1,712.9 Cr | ₹1,690.2 Cr | ₹1,595.5 Cr |
| Cost of Materials Consumed | ₹642.8 Cr | ₹592.1 Cr | ₹564.9 Cr | ₹520.5 Cr | ₹584 Cr | ₹467 Cr | ₹469 Cr | ₹465.3 Cr | ₹49.73 Cr | ₹431.5 Cr | ₹464.4 Cr | ₹428.1 Cr |
| Purchases of Stock-in-Trade | ₹84.5 Cr | ₹82 Cr | ₹73.6 Cr | ₹73 Cr | ₹84.8 Cr | ₹81.2 Cr | ₹69.3 Cr | ₹61.8 Cr | ₹5.39 Cr | ₹71.8 Cr | ₹58.4 Cr | ₹57.1 Cr |
| Changes in Inventories | -₹14 Cr | ₹42.2 Cr | -₹42 Cr | ₹24.7 Cr | -₹42.7 Cr | ₹26.2 Cr | ₹16.5 Cr | ₹34.6 Cr | -₹2.38 Cr | ₹32.6 Cr | ₹34.5 Cr | ₹34.9 Cr |
| Employee Benefit Expense | ₹766.9 Cr | ₹706.4 Cr | ₹636.2 Cr | ₹591.1 Cr | ₹590.6 Cr | ₹560.1 Cr | ₹564.3 Cr | ₹552.9 Cr | ₹55.5 Cr | ₹581.5 Cr | ₹531.8 Cr | ₹547.7 Cr |
| Finance Costs | ₹56.5 Cr | ₹56.1 Cr | ₹50.2 Cr | ₹49 Cr | ₹52.7 Cr | ₹55.6 Cr | ₹61 Cr | ₹71 Cr | ₹7.3 Cr | ₹71.3 Cr | ₹66.1 Cr | ₹61.9 Cr |
| Depreciation & Amortisation | ₹116.8 Cr | ₹120.7 Cr | ₹104.8 Cr | ₹98.1 Cr | ₹95.2 Cr | ₹91.3 Cr | ₹91.4 Cr | ₹90.7 Cr | ₹10.1 Cr | ₹94.6 Cr | ₹96.6 Cr | ₹89.7 Cr |
| Other Expenses | ₹470.5 Cr | ₹410.3 Cr | ₹392.3 Cr | ₹401.8 Cr | ₹366.7 Cr | ₹399.8 Cr | ₹343.8 Cr | ₹365.6 Cr | ₹40.48 Cr | ₹341.7 Cr | ₹349.4 Cr | ₹349.5 Cr |
| Total Expenses | ₹2,124 Cr | ₹2,009.8 Cr | ₹1,780 Cr | ₹1,758.2 Cr | ₹1,731.3 Cr | ₹1,681.2 Cr | ₹1,615.3 Cr | ₹1,641.9 Cr | ₹166.12 Cr | ₹1,625 Cr | ₹1,601.2 Cr | ₹1,568.9 Cr |
| Profit Before Exceptional Items & Tax | ₹189.7 Cr | ₹133.2 Cr | ₹196.2 Cr | ₹154.5 Cr | ₹209.4 Cr | ₹149.7 Cr | ₹158.7 Cr | ₹103.8 Cr | ₹11.18 Cr | ₹87.9 Cr | ₹89 Cr | ₹26.6 Cr |
| Exceptional Items | -₹13.7 Cr | -₹39.7 Cr | -₹5.8 Cr | ₹0 | -₹3.3 Cr | -₹18.9 Cr | -₹14.2 Cr | ₹395.9 Cr | -₹16.89 Cr | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹176 Cr | ₹93.5 Cr | ₹190.4 Cr | ₹154.5 Cr | ₹206.1 Cr | ₹130.8 Cr | ₹144.5 Cr | ₹499.7 Cr | -₹5.71 Cr | ₹87.9 Cr | ₹89 Cr | ₹26.6 Cr |
| Total Tax Expense | ₹56.7 Cr | ₹37.6 Cr | ₹70.4 Cr | ₹51.9 Cr | ₹54.7 Cr | ₹29.8 Cr | ₹41.9 Cr | ₹17.9 Cr | ₹81 Lakh | ₹34.6 Cr | ₹35.9 Cr | ₹19.2 Cr |
| Net Profit | ₹119.3 Cr | ₹55.8 Cr | ₹119.9 Cr | ₹102.5 Cr | ₹151.3 Cr | ₹100.7 Cr | ₹102.5 Cr | ₹481.8 Cr | -₹6.18 Cr | ₹66.4 Cr | ₹62.1 Cr | ₹6 Cr |
| attributable to Owners | ₹119.4 Cr | ₹55.9 Cr | ₹120.3 Cr | ₹102.9 Cr | ₹153.6 Cr | ₹100.9 Cr | ₹102.8 Cr | ₹482.1 Cr | -₹5.86 Cr | ₹66.8 Cr | ₹62.5 Cr | ₹6.4 Cr |
| attributable to NCI | -₹10 Lakh | -₹10 Lakh | -₹40 Lakh | -₹40 Lakh | -₹2.3 Cr | -₹20 Lakh | -₹30 Lakh | -₹30 Lakh | -₹32 Lakh | -₹40 Lakh | -₹40 Lakh | -₹40 Lakh |
| Other Comprehensive Income | ₹281.9 Cr | ₹62.4 Cr | ₹160.4 Cr | ₹41.1 Cr | -₹4.6 Cr | ₹63.5 Cr | ₹30 Cr | -₹3.9 Cr | -₹66 Lakh | ₹17 Cr | ₹34.2 Cr | ₹9.8 Cr |
| Total Comprehensive Income | ₹401.2 Cr | ₹118.2 Cr | ₹280.3 Cr | ₹143.6 Cr | ₹146.7 Cr | ₹164.2 Cr | ₹132.5 Cr | ₹477.9 Cr | -₹6.84 Cr | ₹83.4 Cr | ₹96.3 Cr | ₹15.8 Cr |
| EBITDA (computed) | ₹363 Cr | ₹310 Cr | ₹351.2 Cr | ₹301.6 Cr | ₹357.3 Cr | ₹296.6 Cr | ₹311.1 Cr | ₹265.5 Cr | ₹28.58 Cr | ₹253.8 Cr | ₹251.7 Cr | ₹178.2 Cr |
| Basic EPS | ₹7.55 | ₹3.52 | ₹7.59 | ₹6.49 | ₹9.71 | ₹6.37 | ₹6.47 | ₹30.44 | ₹-3.69 | ₹4.22 | ₹3.94 | ₹0.40 |
| Diluted EPS | ₹7.52 | ₹3.52 | ₹7.57 | ₹6.47 | ₹9.68 | ₹6.36 | ₹6.46 | ₹30.35 | ₹-3.68 | ₹4.20 | ₹3.94 | ₹0.40 |
| Segment · Q4 FY26 (latest quarter) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Radiopharma | ₹990 Cr | ₹77.8 Cr | ₹3,679.2 Cr | ₹1,239.4 Cr |
| Allergy Immunotherapy | ₹217.6 Cr | ₹89.8 Cr | ₹631 Cr | ₹131 Cr |
| Contract Development and Manufacturing Organisation - Sterile Injectables | ₹546.5 Cr | ₹55.9 Cr | ₹6,058.3 Cr | ₹2,785.2 Cr |
| Contract Research, Development and Manufacturing Organisation | ₹334.8 Cr | ₹36 Cr | ₹1,772.7 Cr | ₹441.7 Cr |
| Generics | ₹214.4 Cr | ₹17.4 Cr | ₹1,241.9 Cr | ₹259.4 Cr |
| Proprietary Novel Drugs | ₹0 | -₹7.4 Cr | ₹330.8 Cr | ₹9.8 Cr |
| Unallocable corporate | ₹14.8 Cr | ₹0 | ₹1,808.8 Cr | ₹3,560.6 Cr |
| Segment · FY 2026 (annual) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Radiopharma | ₹3,690.1 Cr | ₹359.9 Cr | - | - |
| Allergy Immunotherapy | ₹795.7 Cr | ₹271.7 Cr | - | - |
| Contract Development and Manufacturing Organisation - Sterile Injectables | ₹1,812.6 Cr | ₹206.3 Cr | - | - |
| Contract Research, Development and Manufacturing Organisation | ₹1,264.9 Cr | ₹123.8 Cr | - | - |
| Generics | ₹773.5 Cr | ₹27.6 Cr | - | - |
| Proprietary Novel Drugs | ₹0 | -₹19.4 Cr | - | - |
| Unallocable corporate | ₹58.5 Cr | ₹0 | - | - |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹263.5 Cr | ₹745.7 Cr | ₹784.7 Cr | ₹810.12 Cr | ₹87.75 Cr | ₹2,709.5 Cr | ₹3,139.9 Cr |
| Other Income | ₹2.4 Cr | ₹99.6 Cr | ₹103.4 Cr | ₹137.89 Cr | ₹125.87 Cr | ₹47.88 Cr | ₹173.23 Cr |
| Total Income | ₹265.9 Cr | ₹845.3 Cr | ₹888.1 Cr | ₹948.01 Cr | ₹213.62 Cr | ₹2,757.38 Cr | ₹3,313.13 Cr |
| Cost of Materials Consumed | ₹0 | ₹282.5 Cr | ₹310 Cr | ₹396.3 Cr | ₹0 | ₹1,328.92 Cr | ₹1,683.29 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹6.5 Cr | ₹14.81 Cr | ₹0 | ₹66.23 Cr | ₹109.46 Cr |
| Changes in Inventories | ₹0 | -₹6.7 Cr | ₹39 Cr | ₹3.45 Cr | ₹0 | ₹55.21 Cr | -₹108.32 Cr |
| Employee Benefit Expense | ₹103.8 Cr | ₹203 Cr | ₹190 Cr | ₹167.27 Cr | ₹49.21 Cr | ₹220.67 Cr | ₹264.9 Cr |
| Finance Costs | ₹7.3 Cr | ₹29.8 Cr | ₹29.9 Cr | ₹18.52 Cr | ₹30.59 Cr | ₹101.8 Cr | ₹136.2 Cr |
| Depreciation & Amortisation | ₹6 Cr | ₹53.1 Cr | ₹48.3 Cr | ₹43.25 Cr | ₹6.25 Cr | ₹99.97 Cr | ₹107.4 Cr |
| Other Expenses | ₹110.9 Cr | ₹234.8 Cr | ₹222.7 Cr | ₹225.07 Cr | ₹45.32 Cr | ₹611.41 Cr | ₹819.66 Cr |
| Total Expenses | ₹228 Cr | ₹796.5 Cr | ₹846.4 Cr | ₹868.67 Cr | ₹131.37 Cr | ₹2,484.21 Cr | ₹3,012.59 Cr |
| Profit Before Exceptional Items & Tax | ₹37.9 Cr | ₹48.8 Cr | ₹41.7 Cr | ₹79.34 Cr | ₹82.25 Cr | ₹273.17 Cr | ₹300.54 Cr |
| Exceptional Items | -₹8.7 Cr | -₹11.2 Cr | ₹0 | ₹0 | ₹0 | ₹0 | -₹1.7 Cr |
| Profit Before Tax | ₹29.2 Cr | ₹37.6 Cr | ₹41.7 Cr | ₹79.34 Cr | ₹82.25 Cr | ₹273.17 Cr | ₹298.84 Cr |
| Total Tax Expense | ₹9.3 Cr | ₹18.4 Cr | ₹10.1 Cr | ₹29.46 Cr | ₹3.75 Cr | ₹58.69 Cr | -₹22.3 Cr |
| Net Profit | ₹63.2 Cr | ₹19.2 Cr | ₹31.6 Cr | ₹49.88 Cr | ₹78.5 Cr | ₹214.48 Cr | ₹321.14 Cr |
| Other Comprehensive Income | -₹90 Lakh | -₹30 Lakh | -₹50 Lakh | ₹1.32 Cr | ₹2 Lakh | -₹1.75 Cr | -₹1.88 Cr |
| Total Comprehensive Income | ₹62.3 Cr | ₹18.9 Cr | ₹31.1 Cr | ₹51.2 Cr | ₹78.52 Cr | ₹212.73 Cr | ₹319.26 Cr |
| EBITDA (computed) | ₹51.2 Cr | ₹131.7 Cr | ₹119.9 Cr | ₹141.11 Cr | ₹119.09 Cr | ₹474.94 Cr | ₹544.14 Cr |
| Basic EPS | ₹1.25 | ₹1.21 | ₹1.99 | ₹3.13 | ₹4.93 | ₹13.47 | ₹20.16 |
| Diluted EPS | ₹1.25 | ₹1.21 | ₹1.99 | ₹3.13 | ₹4.93 | ₹13.47 | ₹20.16 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹2,432.7 Cr | ₹2,909.6 Cr | ₹2,991.9 Cr | ₹3,008.47 Cr |
| Non-current Assets | ₹2,381.8 Cr | ₹2,425.4 Cr | ₹2,451.3 Cr | ₹2,429.59 Cr |
| Current Assets | ₹50.9 Cr | ₹484.2 Cr | ₹540.6 Cr | ₹578.88 Cr |
| Property, Plant & Equipment | ₹95.4 Cr | ₹514.8 Cr | ₹522.6 Cr | ₹491.48 Cr |
| Inventories | ₹0 | ₹232.4 Cr | ₹250.9 Cr | ₹313.6 Cr |
| Trade Receivables | ₹23.8 Cr | ₹206.3 Cr | ₹194.2 Cr | ₹188.52 Cr |
| Cash & Equivalents | ₹10.3 Cr | ₹12.6 Cr | ₹36.1 Cr | ₹10.99 Cr |
| Equity (Net Worth) | ₹2,312.3 Cr | ₹2,318.1 Cr | ₹2,374.5 Cr | ₹2,414.55 Cr |
| Equity Share Capital | ₹15.9 Cr | ₹15.9 Cr | ₹15.9 Cr | ₹15.93 Cr |
| Borrowings (Non-current) | ₹50 Cr | ₹232.8 Cr | ₹246.5 Cr | ₹174 Cr |
| Borrowings (Current) | ₹0 | ₹73.3 Cr | ₹96.4 Cr | ₹127.5 Cr |
| Total Debt (computed) | ₹50 Cr | ₹306.1 Cr | ₹342.9 Cr | ₹301.5 Cr |
| Current Liabilities | ₹56.7 Cr | ₹310.3 Cr | ₹315.4 Cr | ₹361.19 Cr |
| Total Liabilities | ₹120.4 Cr | ₹591.5 Cr | ₹617.4 Cr | ₹593.92 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹93.6 Cr | ₹135.6 Cr | ₹143.2 Cr | -₹65.12 Cr | -₹6.47 Cr |
| Investing Cash Flow | ₹34 Cr | -₹2.3 Cr | -₹40.3 Cr | ₹31.07 Cr | ₹96.02 Cr |
| Financing Cash Flow | -₹129.9 Cr | -₹156.8 Cr | -₹77.8 Cr | ₹22.51 Cr | -₹107.37 Cr |
| Capital Expenditure | ₹19.5 Cr | ₹21.4 Cr | ₹67.6 Cr | ₹59.53 Cr | ₹1.95 Cr |
| Free Cash Flow (computed) | ₹74.1 Cr | ₹114.2 Cr | ₹75.6 Cr | -₹124.65 Cr | -₹8.42 Cr |
| Dividends Paid | ₹79.8 Cr | ₹80 Cr | ₹80.2 Cr | ₹80.06 Cr | ₹80.11 Cr |
| Net Change in Cash | -₹2.3 Cr | -₹23.5 Cr | ₹25.1 Cr | -₹11.54 Cr | -₹17.82 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹70.3 Cr | ₹67.3 Cr | ₹66.4 Cr | ₹59.5 Cr | ₹217.3 Cr | ₹196 Cr | ₹165.7 Cr | ₹166.7 Cr | ₹205.8 Cr | ₹175.2 Cr | ₹186.3 Cr | ₹217.4 Cr |
| Other Income | ₹50 Lakh | ₹40 Lakh | ₹80 Lakh | ₹70 Lakh | ₹17.9 Cr | ₹18.4 Cr | ₹43.8 Cr | ₹19.5 Cr | ₹50.1 Cr | ₹19 Cr | ₹18.4 Cr | ₹15.9 Cr |
| Total Income | ₹70.8 Cr | ₹67.7 Cr | ₹67.2 Cr | ₹60.2 Cr | ₹235.2 Cr | ₹214.4 Cr | ₹209.5 Cr | ₹186.2 Cr | ₹255.9 Cr | ₹194.2 Cr | ₹204.7 Cr | ₹233.3 Cr |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹0 | ₹0 | ₹78 Cr | ₹76.8 Cr | ₹62.2 Cr | ₹65.5 Cr | ₹74.1 Cr | ₹69.1 Cr | ₹94.9 Cr | ₹71.9 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | -₹1.5 Cr | ₹3.9 Cr | ₹1.5 Cr | ₹2.6 Cr |
| Changes in Inventories | ₹0 | ₹0 | ₹0 | ₹0 | ₹2.7 Cr | -₹60 Lakh | -₹3.8 Cr | -₹5 Cr | ₹19.3 Cr | -₹1.2 Cr | -₹10.3 Cr | ₹31.2 Cr |
| Employee Benefit Expense | ₹24.8 Cr | ₹29.2 Cr | ₹26.6 Cr | ₹23.2 Cr | ₹50.8 Cr | ₹52.1 Cr | ₹51.4 Cr | ₹48.7 Cr | ₹46.5 Cr | ₹49.9 Cr | ₹46.1 Cr | ₹47.5 Cr |
| Finance Costs | ₹90 Lakh | ₹90 Lakh | ₹2.5 Cr | ₹3 Cr | ₹7 Cr | ₹7.4 Cr | ₹7.8 Cr | ₹7.6 Cr | ₹8.1 Cr | ₹8.3 Cr | ₹7.1 Cr | ₹6.4 Cr |
| Depreciation & Amortisation | ₹1.3 Cr | ₹1.6 Cr | ₹1.6 Cr | ₹1.5 Cr | ₹13.4 Cr | ₹13.3 Cr | ₹13.3 Cr | ₹13.1 Cr | ₹12.7 Cr | ₹12.3 Cr | ₹11.9 Cr | ₹11.4 Cr |
| Other Expenses | ₹31 Cr | ₹25.9 Cr | ₹28 Cr | ₹26 Cr | ₹59.8 Cr | ₹56.7 Cr | ₹62 Cr | ₹56.3 Cr | ₹55.2 Cr | ₹54.2 Cr | ₹53.3 Cr | ₹60 Cr |
| Total Expenses | ₹58 Cr | ₹57.6 Cr | ₹58.7 Cr | ₹53.7 Cr | ₹211.7 Cr | ₹205.7 Cr | ₹192.9 Cr | ₹186.2 Cr | ₹214.4 Cr | ₹196.5 Cr | ₹204.5 Cr | ₹231 Cr |
| Profit Before Exceptional Items & Tax | ₹12.8 Cr | ₹10.1 Cr | ₹8.5 Cr | ₹6.5 Cr | ₹23.5 Cr | ₹8.7 Cr | ₹16.6 Cr | ₹0 | ₹41.5 Cr | -₹2.3 Cr | ₹20 Lakh | ₹2.3 Cr |
| Exceptional Items | -₹8.7 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | -₹11.2 Cr | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹4.1 Cr | ₹10.1 Cr | ₹8.5 Cr | ₹6.5 Cr | ₹23.5 Cr | ₹8.7 Cr | ₹16.6 Cr | -₹11.2 Cr | ₹41.5 Cr | -₹2.3 Cr | ₹20 Lakh | ₹2.3 Cr |
| Total Tax Expense | -₹53.1 Cr | ₹3.5 Cr | ₹56.5 Cr | ₹2.4 Cr | ₹9.9 Cr | ₹3.4 Cr | ₹6.1 Cr | -₹1 Cr | ₹9 Cr | ₹10 Lakh | ₹60 Lakh | ₹40 Lakh |
| Net Profit | ₹57.2 Cr | ₹6.6 Cr | -₹6.4 Cr | ₹5.8 Cr | ₹13.6 Cr | ₹5.3 Cr | ₹10.5 Cr | -₹10.2 Cr | ₹32.5 Cr | -₹2.4 Cr | -₹40 Lakh | ₹1.9 Cr |
| Other Comprehensive Income | -₹10 Lakh | ₹10 Lakh | -₹80 Lakh | -₹10 Lakh | ₹30 Lakh | -₹20 Lakh | -₹20 Lakh | -₹20 Lakh | ₹10 Lakh | -₹20 Lakh | -₹20 Lakh | -₹20 Lakh |
| Total Comprehensive Income | ₹57.1 Cr | ₹6.7 Cr | -₹7.2 Cr | ₹5.7 Cr | ₹13.9 Cr | ₹5.1 Cr | ₹10.3 Cr | -₹10.4 Cr | ₹32.6 Cr | -₹2.6 Cr | -₹60 Lakh | ₹1.7 Cr |
| EBITDA (computed) | ₹15 Cr | ₹12.6 Cr | ₹12.6 Cr | ₹11 Cr | ₹43.9 Cr | ₹29.4 Cr | ₹37.7 Cr | ₹20.7 Cr | ₹62.3 Cr | ₹18.3 Cr | ₹19.2 Cr | ₹20.1 Cr |
| Basic EPS | ₹3.59 | ₹0.42 | ₹-3.02 | ₹0.26 | ₹0.86 | ₹0.33 | ₹0.66 | ₹-0.64 | ₹2.05 | ₹-0.15 | ₹-0.03 | ₹0.12 |
| Diluted EPS | ₹3.59 | ₹0.42 | ₹-3.02 | ₹0.26 | ₹0.86 | ₹0.33 | ₹0.66 | ₹-0.64 | ₹2.05 | ₹-0.15 | ₹-0.03 | ₹0.12 |
| Segment · FY 2021 (annual) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Life Science Ingredients | ₹2,709.5 Cr | ₹381.5 Cr | - | - |
| Pharmaceuticals | ₹0 | ₹0 | - | - |
Shareholding Pattern of Jubilant Pharmova Limited
As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 47.68%, foreign institutional investors hold 15.90%, domestic institutional investors hold 11.62%, retail and other public shareholders hold 24.24% of Jubilant Pharmova Limited. The company had 86,347 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 47.68% | 47.68% | 47.68% | 47.68% | 50.68% | 50.68% |
| Public | 51.76% | 51.75% | 51.69% | 51.77% | 48.77% | 48.77% |
| Employee Trusts | 0.56% | 0.57% | 0.63% | 0.56% | 0.56% | 0.56% |
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 47.68% | 50.68% | 50.68% | 50.68% | 50.68% | 50.68% | 50.68% | 50.68% | 50.68% | 54.02% | 54.02% |
| Public | 51.76% | 48.77% | 48.74% | 49.19% | 49.26% | 49.26% | 49.32% | 49.32% | 47.12% | 43.75% | 43.52% |
| Employee Trusts | 0.56% | 0.56% | 0.58% | 0.13% | 0.07% | 0.07% | 0.00% | 0.01% | 2.20% | 2.23% | 2.45% |
| Promoter change (YoY, %pts) | -3.00 | +0.00 | +0.00 | +0.00 | +0.00 | +0.00 | +0.00 | +0.00 | -3.34 | +0.00 | - |
Board & Governance of Jubilant Pharmova Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Jubilant Pharmova Limited has 10 directors - 6 independent and 2 executive. The board is chaired by Shyam Sunder Bhartia.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| Shyam Sunder Bhartia | Non-Executive - Non Independent Director · Chairperson | 1978-06-21 | 4 |
| Hari Shanker Bhartia | Non-Executive - Non Independent Director | 1983-11-01 | 6 |
| Sushil Kumar Roongta | Non-Executive - Independent Director | 2017-05-23 | 6 |
| Vivek Mehra | Non-Executive - Independent Director | 2017-05-23 | 6 |
| Arun Seth | Non-Executive - Independent Director | 2018-10-22 | 4 |
| Shirish Gundopant Belapure | Non-Executive - Independent Director | 2023-03-07 | 4 |
| Priyavrat Bhartia | Executive Director · MD | 2017-05-23 | 6 |
| Arjun Shanker Bhartia | Executive Director · MD | 2017-05-23 | 3 |
| Shivpriya Nanda | Non-Executive - Independent Director | 2024-04-01 | 2 |
| Harsh Mahajan | Non-Executive - Independent Director | 2024-04-01 | 1 |
| Committee | Members |
|---|---|
| Audit Committee | Vivek Mehra (Chairperson), Sushil Kumar Roongta, Arun Seth, Shivpriya Nanda |
| Nomination and remuneration committee | Sushil Kumar Roongta (Chairperson), Shyam Sunder Bhartia, Vivek Mehra, Arun Seth |
| Stakeholders Relationship Committee | Arun Seth (Chairperson), Priyavrat Bhartia, Harsh Mahajan, Shivpriya Nanda |
| Risk Management Committee | Sushil Kumar Roongta (Chairperson), Arun Seth, Shirish Gundopant Belapure, Priyavrat Bhartia, Arjun Shanker Bhartia, Vivek Mehra, Shivpriya Nanda, Harsh Mahajan |
| Corporate Social Responsibility Committee | Shivpriya Nanda (Chairperson), Sushil Kumar Roongta, Priyavrat Bhartia, Arjun Shanker Bhartia, Shirish Gundopant Belapure, Arun Seth, Harsh Mahajan |
Group Structure of Jubilant Pharmova Limited
Jubilant Pharmova Limited has 7 subsidiary companies. This group structure data is as of FY 2022. The corporate group structure reflects Jubilant Pharmova Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Jubilant Generics Limited | U24100UP2013FLC060821 | - |
| Jubilant Biosys Limited | U24110UP1998PLC029591 | - |
| Jubilant Clinsys Limited | U24232UP2004PLC029008 | - |
| Jubilant First Trust Healthcare Limited | U74110UP2006PLC035993 | - |
| Jubilant Draximage Limited | U74900UP2009FLC038194 | - |
| Jubilant Therapeutics India Limited | U74994UP2019PLC114901 | - |
Showing major subsidiaries. Total: 7.
Charges & Borrowings of Jubilant Pharmova Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Aug 2025 | Others | ₹50 Cr | Open |
| 28 Aug 2023 | Others | ₹100 Cr | Open |
| 23 Mar 2023 | Yes Bank Limited | ₹50 Cr | Open |
| 15 Feb 2023 | Others | ₹60 Cr | Open |
| 26 Feb 2024 | Hdfc Bank Limited | ₹100 Cr | Satisfied |
Total charge records: 84 View all charges
Employees and EPFO Compliance at Jubilant Pharmova Limited
Jubilant Pharmova Limited has a workforce of 1,055 employees as of Mar 30, 2024.
Employee and EPFO history for Jubilant Pharmova Limited
Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Jubilant Pharmova Limited
GST registrations and filing compliance for Jubilant Pharmova Limited
State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Jubilant Pharmova Limited
Credit ratings, litigation, and regulatory alerts for Jubilant Pharmova Limited
Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Jubilant Pharmova Limited
MSME payment history for Jubilant Pharmova Limited
Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Jubilant Pharmova Limited
Corporate group structure for Jubilant Pharmova Limited
Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Jubilant Pharmova Limited
MCA filings and documents for Jubilant Pharmova Limited
Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Jubilant Pharmova Limited
Recent News on Jubilant Pharmova Limited
Frequently Asked Questions about Jubilant Pharmova Limited
Jubilant Pharmova Limited is an active public limited company in the pharma sector based in U P, Uttar Pradesh, India. It was incorporated on 21 June 1978 (48+ years old) and is registered under CIN L24116UP1978PLC004624. Listed on BSE: 530019 and NSE: JUBLPHARMA. The company has 1,055 employees.
Jubilant Pharmova Limited reported revenue of ₹8,279.6 Cr for FY 2026 (up 14.45% YoY) based on consolidated NSE filings.
The current directors of Jubilant Pharmova Limited are:
- Priyavrat Bhartia - Managing Director
- Arun Seth - Director
- Hari Shanker Bhartia - Director
- Arjun Shanker Bhartia - Managing Director
- Shyam Sunder Bhartia - Director
- Vivek Mehra - Director
- Sushil Kumar Roongta - Director
- Shirish Gundopant Belapure - Director
- Shivpriya Nanda - Director
- Harsh Mahajan - Director
The primary industry of Jubilant Pharmova Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.
Yes. Jubilant Pharmova Limited is listed on both BSE (code: 530019) and NSE (symbol: JUBLPHARMA).
Jubilant Pharmova Limited can be reached at the registered office: Bhartiagram Gajraulajyotiba Phoolay Nagar, U P, Uttar Pradesh, India – 244223, or through the website jubilantpharmova.com.